NCT01466868终止2 期
A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 22
- 试验地点
- 13
- 主要终点
- evaluation of the antitumor activity of MK-2206 in terms of objective response rate (ORR).
研究概览
简要总结
The purpose of this study is to evaluate the antitumor efficacy and the safety of MK 2206 in patients with relapsed or refractory diffuse large B cell lymphoma.
详细描述
Diffuse Large B-cell Lymphoma (DLBCL) is the most frequent subtype of Non-Hodgkin lymphoma (NHL) around the world, in all age groups.
DLBCL is a curable disease and combination of monoclonal antibody against CD20 (rituximab) with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen have improved the prognosis of patients with a 20% increase of the cure rate. For the remaining patients who are not in complete response and/or who relapse after first line therapy, the possibility of cure is dramatically reduced.
As PI3K/AKT/mTOR pathway regulates the expression of cyclin D1, c-Myc and Stat3 proteins, which are involved in the pathogenesis of DLBCL HL), this signalling axis is an emerging therapeutic target for treatment of DLBCL.
One study has shown that the level of p-Akt is an adverse prognostic feature in DLBCL and is found in 52% of tumors samples from DLBCL patients.
Given the fact that AKT is overactivated in about to 52% of DLBCL and is considered as a poor prognosis factor, we postulate that targeting AKT in DLBCL may be an interesting therapeutic strategy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed diffuse large B-Cell lymphomas.
- •Patients must have measurable disease.
- •Subjects must have received at least two prior treatment lines.There is no maximal limit on the number of prior therapies
- •Prior treatment must include CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) -like chemotherapy in combination with rituximab. Rituximab used alone is not considered as a separate regimen.
- •Prior treatment could include high dose chemotherapy with autologous stem-cell transplantation if patients had progressed ≥ 3 months after this treatment.
- •Salvage treatment, mobilization chemotherapy, high-dose chemotherapy and planned post-transplant therapy should be considered as one regimen
- •Relapsed or refractory patients who are candidate to high-dose chemotherapy and autologous or allogenic stem cell transplantation are not eligible.
- •Patients must have discontinued all prior therapies for at least 5 times the t1/2 of prior anti-cancer therapies before study entry.
- •Male or female patients, age ≥ 18 years.
- •Life expectancy greater than 4 months.
- •ECOG performance status ≤
- •Patients must have normal organ and marrow function as defined below:
- •Absolute neutrophil count ≥ 1.5 x 109/L,
- •Platelet count ≥ 100 x 109/L or ≥75 x 109/L if the bone marrow is involved,
- •AST/ALT ≤ 2.5 x upper limit of normal (ULN) (or ≤ 5.0 x ULN if liver metastasis) direct bilirubin ≤ 1.5ULN
- •Calculated creatinine clearance (Cockcroft-Gault formula) of ≥ 50mL/min
- •Patients must agree to use adequate double contraception
- •Patients must be able to swallow whole tablets.
- •Cardiovascular baseline QTcF≤ 450 msec (male) or QTcF≤470msec (female).
- •Signed written informed consent document.
- •Patients with French Social Security in compliance with the French law relating to biomedical research.
排除标准
- •Tumor tissue sample not available for pathological review.
- •Patients with others than Diffuse large B-Cell Lymphoma histology.
- •Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.
- •Patients who have not recovered from adverse events grade > 1 due to agents administered more than 4 weeks earlier.
- •Patients who are receiving any other investigational agents.
- •Patients with known CNS involvement should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the compliance to the study protocol.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 tablets.
- •Patients with uncontrolled hyperglycemia
- •Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant and breastfeeding women are excluded from this study.
- •HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MK-
- •Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption.
- •Patients with clinically important history of liver disease, including viral or other hepatitis or cirrhosis.
- •Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years.
- •Uncontrolled hypertension with resting SBP>140 or resting DBP>90mm Hg
研究组 & 干预措施
MK2206
Experimental
Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
干预措施: MK2206 (Drug)
结局指标
主要结局
evaluation of the antitumor activity of MK-2206 in terms of objective response rate (ORR).
时间窗: 4 months after the first day of treatment.
the objective response rate (ORR) is measured as per 2007 Cheson international response criteria.
次要结局
- duration of response(from the time of first documented response (complete response or partial response) until the first documented disease progression or death due to underlying cancer (up to 3.5 years from the first inclusion))
- evaluation of the antitumor activity of MK-2206 in terms of objective response rate (ORR).(4 months after the first day of treatment)
- progression-free survival(from the date of inclusion to the date of event defined as the first documented disease progression or death from any cause (up to 3.5 years from the first inclusion))
- safety profile(during the treatment and up to 3.5 years from the first inclusion)
- overall survival(from the date of inclusion to the date of death from any cause (up to 3.5 years from the first inclusion))
研究者
研究点 (13)
Loading locations...
相似试验
已完成
1 期
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)Solid TumorsNCT01071018Merck Sharp & Dohme LLC24
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell LymphomaNCT01481129National Cancer Institute (NCI)22
已完成
2 期
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Myeloid LeukemiaNCT01253447National Cancer Institute (NCI)19
已完成
2 期
Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRefractory Hairy Cell LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Large Granular Lymphocyte LeukemiaTesticular LymphomaWaldenström MacroglobulinemiaAnaplastic Large Cell LymphomaNCT01258998National Cancer Institute (NCI)60
终止
2 期
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast CancerEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeHER2/Neu PositiveProgesterone Receptor NegativeProgesterone Receptor PositiveStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-Negative Breast CarcinomaNCT01319539National Cancer Institute (NCI)12